← 產業報告目錄

Cardiometabolic Diseases Market, By Disease Type (Cardiovascular Diseases, Diabetes, Obesity, Chronic Kidney Disease (CKD), and Others), By Product Type (Therapeutics, Diagnostics, and Monitoring Devices), By End User (Hospitals, Specialty Clinics, Homecare Settings, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

出版商 Coherent Market Insights出版日期 2026-07-27頁數 250報告編號 CMR-8a48e1d2dd

授權報價

Single User Price$4,500 USD
Site License Price$7,000 USD
Enterprisewide Price (Global Site License)$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global cardiometabolic diseases market is estimated to be valued at USD 128.74 Bn in 2026 and is expected to reach USD 183.96 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033. Cardiometabolic diseases are a series of diseases including type 2 diabetes, obesity, hypertension, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and atherosclerotic cardiovascular disease (ASCVD). These various cardiometabolic conditions involve several mechanisms, including insulin resistance, inflammation, endothelial dysfunction, and oxidative stress that often led to the concurrence of multiple comorbidities. The global cardiometabolic diseases market includes pharmaceuticals, biologics, diagnostics, devices, and digital solutions used in the prevention, diagnosis, monitoring, and treatment of these diseases. The global cardiometabolic diseases market is growing rapidly owing to the growing obesity and diabetes rates and ageing populace, a lifestyle changes due to an increasingly sedentary habit and expenditure in healthcare on global basis. This rapid expansion in the market size is driven by breakthrough innovations in treatments, especially with the development of GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors, which not only improve cardiometabolic parameters but also cardiometabolic risk. As a result, global insurance payers and expanding reach of smartwatches and remote monitoring technology may support long term market growth. Market Dynamics The global cardiometabolic diseases market is driven by rapidly increasing prevalence of obesity, type 2 diabetes, and cardiovascular diseases, creating sustained demand for advanced therapeutics, diagnostics, and disease management solutions. The growing adoption of innovative therapies, including GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors, along with advancements in digital health, artificial intelligence, and remote patient monitoring, is transforming cardiometabolic care. In addition, continuous investments in research and development of next-generation therapies, such as dual and triple agonists and RNA-based treatments, are further accelerating market growth. However, the growth of the cardiometabolic diseases market is limited by factors such as high cost of novel therapies, limited reimbursement in developing economies, stringent regulatory requirements, and long-term patient adherence issues. Nevertheless, government initiatives aimed at preventive medicine against chronic diseases and increasing demand for telehealth services will offer new opportunities for growth in the cardiometabolic diseases market. Key Features of the Study • This report provides in-depth analysis of the global cardiometabolic diseases market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global cardiometabolic diseases market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Novartis AG, Sanofi, Pfizer Inc., Bayer AG, and Johnson & Johnson • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global cardiometabolic diseases market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiometabolic diseases market Market Segmentation • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Cardiovascular Diseases o Diabetes o Obesity o Chronic Kidney Disease (CKD) o Others • Product Type Insights (Revenue, USD Bn, 2021 - 2033) o Therapeutics o Diagnostics o Monitoring Devices • End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Specialty Clinics o Homecare Settings o Others • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Novo Nordisk A/S o Eli Lilly and Company o AstraZeneca PLC o Boehringer Ingelheim International GmbH o Merck & Co., Inc. o Novartis AG o Sanofi o Pfizer Inc. o Bayer AG o Johnson & Johnson
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Cardiometabolic Diseases Market, By Disease Type  Global Cardiometabolic Diseases Market, By Product Type  Global Cardiometabolic Diseases Market, By End User  Global Cardiometabolic Diseases Market, By Distribution Channel  Global Cardiometabolic Diseases Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Industry Trends 4. Global Cardiometabolic Diseases Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cardiovascular Diseases  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Diabetes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Obesity  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Chronic Kidney Disease (CKD)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Cardiometabolic Diseases Market, By Product Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Therapeutics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Diagnostics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Monitoring Devices  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Cardiometabolic Diseases Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Specialty Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Homecare Settings  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Cardiometabolic Diseases Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Cardiometabolic Diseases Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o Novo Nordisk A/S  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca PLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Boehringer Ingelheim International GmbH  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bayer AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Cardiometabolic Diseases Market' - Global forecast to 2033
圖表清單 List of Tables & Figures
NA NA

提及公司

o Novo Nordisk A/So Eli Lilly and Companyo AstraZeneca PLCo Boehringer Ingelheim International GmbHo Merck & Co.Inc.o Novartis AGo Sanofio Pfizer Inc.o Bayer AGo Johnson & Johnson

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們